45
Participants
Start Date
August 31, 2013
Primary Completion Date
December 8, 2020
Study Completion Date
February 16, 2021
oral rigosertib
Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle.
Azacitidine
Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
Mount Sinai Medical Center, New York
White Plains Hospital Center for Cancer Care, White Plains
Roswell Park Cancer Institute, Buffalo
Carolina Blood and Cancer Care Associates, Rock Hill
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Rush University Medical Center, Chicago
Saint Louis University, St Louis
Cancer Center of Kansas, Wichita
Hôpital St. Louis, Paris
The University of Texas MD Anderson Cancer Center, Houston
Banner MD Anderson Cancer Center, Gilbert
City of Hope, Duarte
Desert Hematology Oncology Medical Group, Inc., Rancho Mirage
Traws Pharma, Inc.
INDUSTRY